MYD88 and diffuse large B-cell lymphoma: In human lymphoma cell lines and primary lymphoma cells, cerdulatinib demonstrates broad anti-tumor activity in diffuse large B-cell lymphoma including GCB and ABC tumor cells with ibrutinib-resistant MYD88 or CARD11 mutations [25].